Skip to Content

Enfuvirtide Pregnancy and Breastfeeding Warnings

Enfuvirtide is also known as: Fuzeon

Enfuvirtide Pregnancy Warnings

An Antiretroviral Pregnancy Registry has been established to monitor maternal-fetal outcome of enfuvirtide exposures during pregnancy. To register patients, physicians should call 800-258-4263 (USA).

Enfuvirtide has been assigned to pregnancy category B by the FDA. Animal studies have failed to reveal evidence of fetal harm. There are no controlled data in human pregnancy. Enfuvirtide is only recommended for use during pregnancy when benefit outweighs risk.

See references

Enfuvirtide Breastfeeding Warnings

There are no data on the excretion of enfuvirtide into human milk. Due to the potential for serious adverse reactions in nursing infants mothers should be advised not to breast-feed during enfuvirtide therapy. In addition, HIV-infected mothers should not breast-feed their infants due to the risk of transmission of HIV via breast milk.

See references

References for pregnancy information

  1. "Product Information. Fuzeon (enfuvirtide)." Roche Laboratories, Nutley, NJ.
  2. Perinatal HIV Guidelines Working Group "Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available from: URL: http://aidsinfo.nih.gov/c" ([2008 Jul 8]):

References for breastfeeding information

  1. "Product Information. Fuzeon (enfuvirtide)." Roche Laboratories, Nutley, NJ.
  2. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. National Institute of Health "Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available from: URL: http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf." ([2011 Sep 14]):
  3. "Infant feeding and transmission of human immunodeficiency virus in the United States." Pediatrics 131 (2013): 391-6

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide